SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the six months ended January 31, 2015.
FINANCIAL RESULTS
For the six months ended January 31, 2015, OncoSec reported a net loss of $8.7 million, or $0.04 per share, compared to a net loss of $4.7 million, or $0.03 per share, for the same period last year. There were no revenues for the six months ended January 31, 2015 or January 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
